774608-13-8

Usage

Uses

Used in Pharmaceutical Industry:
Boronic acid, (5-bromo-2-methylphenyl)(9CI) is used as a key intermediate in the synthesis of pharmaceuticals for its ability to facilitate the formation of complex molecular structures. Its role in creating carbon-carbon and carbon-heteroatom bonds is crucial for the development of novel drugs with potential applications in treating various diseases.
Used in Agrochemical Industry:
In the agrochemical sector, Boronic acid, (5-bromo-2-methylphenyl)(9CI) is utilized as a precursor in the production of agrochemicals. Its reactivity and bonding capabilities are harnessed to create compounds that can enhance crop protection and improve agricultural yields.
Used in Chemical Research:
Boronic acid, (5-bromo-2-methylphenyl)(9CI) is employed as a research tool in chemical laboratories to explore new reaction pathways and develop innovative synthetic methods. Its unique properties allow scientists to investigate the mechanisms of bond formation and breakage, contributing to the advancement of organic chemistry.
Used in Enzyme and Protein Inhibition:
Boronic acid, (5-bromo-2-methylphenyl)(9CI) is studied for its potential as an enzyme and protein inhibitor, which can be used in the treatment of diseases such as cancer and diabetes. Its ability to interact with specific biological targets makes it a promising candidate for therapeutic intervention, offering new avenues for drug discovery and development.

Upstream product

• 260558-15-4 4-bromo-2-iodo-1-methylbenzene 
• 121-43-7 Trimethyl borate 
• 1068-55-9 isopropylmagnesium chloride 
• 1008106-91-9 6-butyl-2-(2,5-dibromophenyl)-1,3,6,2-dioxazaborocane 
• 74-88-4 methyl iodide 

Downstream Products

• 774608-08-1 2-amino-4-chloro-6-(2-methyl-5-bromo-phenyl)-pyrimidine 
• 1033760-99-4 5-bromo-2-methylphenyllead triacetate 

Relevant academic research and scientific papers

The influence of boronate groups on the selectivity of the Br-Li exchange in model dibromoaryl boronates

The selectivity of the Br/Li exchange reaction of 6-butyl-2-(2,5- dibromophenyl)-1,3,6,2-dioxazaborocane (2,5-Br2C6H 3B(OCH2CH2)2NBu) and the analogous anionic derivatives, 2,5-Br2C6H3B(OiPr) 3Li and 2,5-Br2C6H3BF3K, was investigated using nBuLi as the lithiating reagent. In the case of the former compound there was a slight preference for lithiation at the 5-position. For 2,5-Br2C6H3B(OiPr)3Li, the lithiation occured exclusively at C5, but for 2,5-Br2C 6H3BF3K, 2-lithiation was preferred. Calculations performed for the lithiation of ortho- and meta-brominated phenyl boronates revealed that ortho-lithiated aryl boronates are thermodynamically more stable, but that the Br/Li exchange is generally dictated by kinetics, which accounts for the variation of selectivity depending on the type of boronate group. In addition, the successful generation of the 2,5-dilithiophenyl boronate species 2,5-Li2C6H3B(OCH 2CH2)2NBu by a double Br/Li interconversion is reported. The Br/Li exchange in the related 6-butyl-2-[3-(2,5-dibromothienyl)]- 1,3,6,2-dioxazaborocane, 2,5-Br2-3-ThB(OCH2CH 2)2NBu, occured preferentially at the 5-position, but the product was readily transformed into the more stable 2-lithiated isomer. The use of 2 equiv. of nBuLi resulted in the efficient formation of the dilithiated species, 2,5-Li2-3-ThB(OCH2CH2)2NBu. The obtained lithiated aryl boronates were converted into functionalized arylboronic acids by treatment with selected electrophiles. The selectivity of the Br/Li exchange in model dibromoaryl boronates was studied in the context of the directing effect of boron-based groups. Theoretical calculations revealed that ortho-lithiated aryl boronates are thermodynamically more stable, but the Br/Li exchange is generally dictated by kinetics. The lithiated aryl and thienyl boronates were converted into functionalized boronic acids. Copyright

Synthesis, SAR, and antitumor properties of diamino-C,N-diarylpyrimidine positional isomers: Inhibitors of lysophosphatidic acid acyltransferase-β

2,4-Diamino-N4,6-diarylpyrimidines were identified as potent, isoform specific inhibitors of lysophosphatidic acid acyltransferase-β (LPAAT-β). Active inhibitors also blocked proliferation of tumor cell lines in vitro. The effect of 2j in an in

Pyrimidines and uses thereof

The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor-cells.